{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:10:14Z","timestamp":1773209414537,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00059-021-05085-4","type":"journal-article","created":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T11:03:01Z","timestamp":1638961381000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnose und Behandlung der kardialen Amyloidose","Diagnosis and treatment of cardiac amyloidosis"],"prefix":"10.1007","volume":"47","author":[{"given":"Sabine","family":"Pankuweit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"issue":"4","key":"5085_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia\u00a0P, Rapezzi\u00a0C, Adler\u00a0Y et al (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail 23(4):512\u2013526","journal-title":"Eur J Heart Fail"},{"key":"5085_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","volume":"25","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Buxbaum\u00a0JN, Eisenberg\u00a0DS et\u00a0al (2018) Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid 25:215\u2013219","journal-title":"Amyloid"},{"key":"5085_CR3","first-page":"159","volume":"117","author":"S Ihne","year":"2020","unstructured":"Ihne\u00a0S, Morbach\u00a0C, Sommer\u00a0C et\u00a0al (2020) Amyloidose \u2013 Diagnostik und Therapie einer unterdiagnostizierten Erkrankung. Amyloidosis\u2014the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int 117:159\u2013166","journal-title":"Dtsch Arztebl Int"},{"key":"5085_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini\u00a0G, Merlini\u00a0G (2016) What is new in diagnosis and management of light chain amyloidosis? Blood 128:159\u2013168","journal-title":"Blood"},{"key":"5085_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz\u00a0MA (2018) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer\u00a0J 8:44","journal-title":"Blood Cancer J"},{"key":"5085_CR6","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez\u00a0E, Gallego-Delgado\u00a0M, Guzzo-Merello\u00a0G et al (2015) Wild-type transthyretin amyloidosis as a\u00a0cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"5085_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen\u00a0M, Peuralinna\u00a0T, Polvikoski\u00a0T et al (2008) Senile systemic amyloidosis affects 25\u202f% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a\u00a0population-based autopsy study. Ann Med 40:232\u2013239","journal-title":"Ann Med"},{"key":"5085_CR8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan\u00a0M, Scott\u00a0CG, Kyle\u00a0RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a\u00a0novel staging system. J\u00a0Am Coll Cardiol 68:1014\u20131020","journal-title":"J Am Coll Cardiol"},{"key":"5085_CR9","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy\u00a0T, Costes\u00a0B, Hag\u00e8ge\u00a0AA et\u00a0al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart\u00a0J 37:1826\u20131834","journal-title":"Eur Heart J"},{"key":"5085_CR10","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Castano","year":"2017","unstructured":"Castano\u00a0A, Narotsky\u00a0DL, Hamid\u00a0N et\u00a0al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart\u00a0J 38:2879\u20132887","journal-title":"Eur Heart J"},{"key":"5085_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini\u00a0M, Cappelli\u00a0F, Chacko\u00a0L et\u00a0al (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13:909\u2013920","journal-title":"JACC Cardiovasc Imaging"},{"key":"5085_CR12","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore\u00a0JD, Maurer\u00a0MS, Falk\u00a0RH et\u00a0al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"5085_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","volume":"55","author":"G Palladini","year":"2009","unstructured":"Palladini\u00a0G, Russo\u00a0P, Bosoni\u00a0T et al (2009) Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55:499\u2013504","journal-title":"Clin Chem"},{"key":"5085_CR14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala\u00a0S, Ando\u00a0Y, Bokhari\u00a0S et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/ SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2011evidence base and standardized methods of imaging. J\u00a0Nucl Cardiol 26:2065\u20132123 (Erratum in: J Nucl Cardiol 2021;28:1761\u20131762)","journal-title":"J Nucl Cardiol"},{"key":"5085_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala\u00a0S, Ando\u00a0Y, Bokhari\u00a0S et al (2020) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/ SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2\u2011diagnostic criteria and appropriate utilization. J\u00a0Nucl Cardiol 27:659\u2013673 (Erratum in: J Nucl Cardiol 2021;28:1763\u20131767)","journal-title":"J Nucl Cardiol"},{"key":"5085_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini\u00a0E, Guidalotti\u00a0PL, Salvi\u00a0F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc\u20113,3\u2011diphosphono\u20111,2\u2011propanodicarboxylic acid scintigraphy. J\u00a0Am Coll Cardiol 46:1076\u20131084","journal-title":"J Am Coll Cardiol"},{"key":"5085_CR17","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/eurheartj\/ehaa091","volume":"41","author":"ME Layoun","year":"2020","unstructured":"Layoun\u00a0ME, Desmarais\u00a0J, Heitner\u00a0SB et al (2020) Hot hearts on bone scintigraphy are not all amyloidosis: hydroxychloroquine-induced restrictive cardiomyopathy. Eur Heart\u00a0J 41:2414","journal-title":"Eur Heart J"},{"key":"5085_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar\u00a0S, Dispenzieri\u00a0A, Lacy\u00a0MQ et\u00a0al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J\u00a0Clin Oncol 30:989\u2013995","journal-title":"J Clin Oncol"},{"key":"5085_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness\u00a0B, Ruberg\u00a0FL, Mussinelli\u00a0R et\u00a0al (2019) Development and validation of a\u00a0survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 133:215\u2013223","journal-title":"Blood"},{"key":"5085_CR20","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore\u00a0JD, Damy\u00a0T, Fontana\u00a0M et\u00a0al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart\u00a0J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"5085_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","volume":"2","author":"RK Cheng","year":"2020","unstructured":"Cheng\u00a0RK, Levy\u00a0WC, Vasbinder\u00a0A et\u00a0al (2020) Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol 2:414\u2013424","journal-title":"JACC CardioOncol"},{"key":"5085_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"5085_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cjca.2019.11.032","volume":"36","author":"E Muchtar","year":"2020","unstructured":"Muchtar\u00a0E, Grace\u00a0L, Grogan\u00a0M (2020) The challenges in chemotherapy and stem cell transplantation for light-chain amyloidosis. Can J Cardiol 36:384\u2013395","journal-title":"Can J Cardiol"},{"key":"5085_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.medcli.2020.06.064","volume":"156","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia\u00a0P, Dom\u0131nguez\u00a0F, Gonzalez-Lopez\u00a0E (2021) Transthyretin amyloid cardiomyopathy. Med Clin (Barc) 156:126\u2013134","journal-title":"Med Clin (Barc)"},{"key":"5085_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.hoc.2020.07.006","volume":"34","author":"SE Saith","year":"2020","unstructured":"Saith\u00a0SE, Maurer\u00a0MS, Patel\u00a0AR (2020) Systemic amyloidosis due to monoclonal immunoglobulins. Hematol Oncol Clin North Am 34:1055\u20131068","journal-title":"Hematol Oncol Clin North Am"},{"key":"5085_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi\u00a0C, Elliott\u00a0P, Damy\u00a0T et al (2021) Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT. JACC Heart Fail 9:115\u2013123","journal-title":"JACC Heart Fail"},{"key":"5085_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzalez-Duarte\u00a0A, O\u2019Riordan\u00a0WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"5085_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"5085_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","volume":"26","author":"I Conceicao","year":"2019","unstructured":"Conceicao\u00a0I, Coelho\u00a0T, Rapezzi\u00a0C et\u00a0al (2019) Assessment of patients with hereditary transthyretin amyloidosis\u2014understanding the impact of management and disease progression. Amyloid 26:103\u2013111","journal-title":"Amyloid"}],"updated-by":[{"DOI":"10.1007\/s00059-022-05100-2","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000}}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05085-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05085-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T07:02:52Z","timestamp":1647586972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05085-4"}},"subtitle":["Positionspapier der ESC Working Group on Myocardial and Pericardial Diseases 2021","A position statement of the ESC working group on myocardial and pericardial diseases 2021"],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5085"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05085-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,8]]},"assertion":[{"value":"4 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00059-022-05100-2","URL":"https:\/\/doi.org\/10.1007\/s00059-022-05100-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Pankuweit und R.\u00a0D\u00f6rr geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}